An independent cohort of patients with advanced melanoma treated with pembrolizumab was analyzed by flow cytometry, supporting the relationship between reinvigorated CD8 T cells in the blood and tumor burden, and the correlation with clinical outcome. This evidence concerns the gene CD8A and neoplasm.